Akari Therapeutics plc ADS (AKTX) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, AKTX scores 37 out of 100 with a letter grade of D- and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars, the Fundamental Cash Engine scores 8 of 20 (ROIC of -35%; FCF yield of 0%), indicating the business is not currently generating returns on invested capital or free cash flow. The Whale 13F Flow pillar scores 5 of 20 for institutional accumulation and options positioning, the Insider Conviction pillar scores 5 of 20 for SEC Form 4 and Congressional PTR cluster flow, the Macro Regime Fit pillar scores 9 of 20 (Beta 1.0; sector sensitivity), and the Forensic Balance Sheet pillar scores 10 of 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

For a prospective investor evaluating the stock today, the rating points to a weak fundamental and flow profile. The absence of revenue and negative returns on capital mean valuation cannot be anchored to current earnings or cash generation, so any upside case depends on future developments not captured in this source data. The low Piotroski score and weak flow pillars suggest limited internal momentum and limited institutional or insider conviction. The Altman Z of 2.5 and Debt/Equity of 0.5 provide some balance sheet cushion relative to the cash-burn profile, but the source data does not establish runway length. Overall, the rating frames the stock as elevated-risk and low-visibility rather than as a candidate for a constructive position on these facts alone. This is educational analysis, not personalized financial advice.

Akari Therapeutics plc ADS (AKTX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, the market capitalization is reported as $0.0B, while the market data shows $18.3M. Per the SEC financials, the company reported $0.0M of revenue in FY 2025 and FY 2024, and $0.4M in FY 2023. Not available in source data for product lines, customers, or revenue model specifics.

Per the SEC financials and market data, the company reported operating losses across all three periods and free cash flow outflows of $-10.6M, $-12.6M, and $-16.4M. Gross, operating, and net margins are each reported as 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Cash was $5.2M at the end of FY 2025 and $0.0M at the end of FY 2024; FY 2023 cash and all debt figures are not available in source data.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Not available in source data for upstream suppliers, downstream customers, or sector correlation mappings beyond the Health Care sector and Biotechnology: Pharmaceutical Preparations industry classification.